Início › Síndromes Mielodisplásicas › Ohio
Ensaios clínicos de Síndromes Mielodisplásicas em Ohio
22 estudos para Síndromes Mielodisplásicas estão buscando participantes em locais em Ohio.
Cidades em Ohio
Texto oficial do estudo (Inglês)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Cleveland clinic OH, Cleveland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT07422480Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
RecrutandoEstudo observacional
2 Months · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT00900198Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT03471260Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- e mais 3
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic - Cleveland, Cleveland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06499285Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT05308264A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Canton
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jun. de 2026 · NCT068478675-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
RecrutandoFase 1 inicial
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mai. de 2026 · NCT04187703A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de abr. de 2026 · NCT04256317Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Ohio State University Medical Center, Columbus
RecrutandoFase 1
Idades de 18 a 65 · Todos os sexos · Atualizado em 25 de mar. de 2026 · NCT03533816A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de mar. de 2026 · NCT06543381HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecrutandoFase 2
3 Months · Todos os sexos · Atualizado em 12 de nov. de 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2025 · NCT06501196HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
RecrutandoEstudo observacional
Idades de 12 a 80 · Todos os sexos · Atualizado em 28 de ago. de 2025 · NCT07145411Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.